- Home
- VGM vs RGNX Comparison
VGM vs RGNX Comparison
Compare VGM & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VGM
- RGNX
- Stock Information
- Founded
- VGM 1992
- RGNX 2008
- Country
- VGM United States
- RGNX United States
- Employees
- VGM N/A
- RGNX N/A
- Industry
- VGM Trusts Except Educational Religious and Charitable
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VGM Finance
- RGNX Health Care
- Exchange
- VGM Nasdaq
- RGNX Nasdaq
- Market Cap
- VGM 522.8M
- RGNX 451.1M
- IPO Year
- VGM N/A
- RGNX 2015
- Fundamental
- Price
- VGM $9.71
- RGNX $9.71
- Analyst Decision
- VGM
- RGNX Strong Buy
- Analyst Count
- VGM 0
- RGNX 8
- Target Price
- VGM N/A
- RGNX $28.50
- AVG Volume (30 Days)
- VGM 186.2K
- RGNX 673.5K
- Earning Date
- VGM 01-01-0001
- RGNX 11-05-2025
- Dividend Yield
- VGM 4.34%
- RGNX N/A
- EPS Growth
- VGM N/A
- RGNX N/A
- EPS
- VGM 0.01
- RGNX N/A
- Revenue
- VGM N/A
- RGNX $155,782,000.00
- Revenue This Year
- VGM N/A
- RGNX $260.25
- Revenue Next Year
- VGM N/A
- RGNX N/A
- P/E Ratio
- VGM $988.00
- RGNX N/A
- Revenue Growth
- VGM N/A
- RGNX 74.95
- 52 Week Low
- VGM $8.15
- RGNX $5.04
- 52 Week High
- VGM $10.07
- RGNX $13.48
- Technical
- Relative Strength Index (RSI)
- VGM 67.17
- RGNX 60.66
- Support Level
- VGM $9.52
- RGNX $8.68
- Resistance Level
- VGM $9.56
- RGNX $9.19
- Average True Range (ATR)
- VGM 0.06
- RGNX 0.50
- MACD
- VGM 0.00
- RGNX 0.12
- Stochastic Oscillator
- VGM 93.20
- RGNX 87.85
About VGM Invesco Trust for Investment Grade Municipals (DE)
Invesco Trust for Investment Grade Municipals is active in the financial services sector. Its investment objective is to provide common shareholders with a high level of current income exempt from federal income tax, consistent with preservation of capital.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.